Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Daniella R. A. I. Berry"'
Autor:
Esther E. E. Drees, Yvonne W. S. Jauw, Erik van Dijk, Sven Borchmann, Sandra A. W. M. Verkuijlen, Phylicia Stathi, Nils J. Groenewegen, Nathalie J. Hijmering, Daniella R. A. I. Berry, Eric J. Meershoek, Danielle Hoogmoed, Anne Kwakman, Tessa J. Molenaar, Dirk M. Pegtel, Bauke Ylstra, Daphne de Jong, Josée M. Zijlstra, Margaretha G. M. Roemer
Publikováno v:
HemaSphere, Vol 6, Iss 7, p e749 (2022)
Externí odkaz:
https://doaj.org/article/26363f9c16cc417598430c0d786f8904
Autor:
Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra, Anne T. Gelderloos, Daniella R. A. I. Berry, Nathalie J. Hijmering, Hendrik F. van Essen, Daphne de Jong, Martine E. D. Chamuleau, Sonja Zweegman, Esther C. W. Breij, Margaretha G. M. Roemer, Tuna Mutis
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Abstract Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsie
Externí odkaz:
https://doaj.org/article/1763543d37b64f68b1819cf9d59358d5
Autor:
A. Marijne Heeren, Ilse van Dijk, Daniella R. A. I. Berry, Maryam Khelil, Debbie Ferns, Jeroen Kole, René J. P. Musters, Victor L. Thijssen, Constantijne H. Mom, Gemma G. Kenter, Maaike C. G. Bleeker, Tanja D. de Gruijl, Ekaterina S. Jordanova
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
The indoleamine 2,3-dioxygenase (IDO) enzyme can act as an immunoregulator by inhibiting T cell function via the degradation of the essential amino acid tryptophan (trp) into kynurenine (kyn) and its derivates. The kyn/trp ratio in serum is a prognos
Externí odkaz:
https://doaj.org/article/04e4616045a84d9fa31dbba93fbc5cf5
Autor:
Ida H. Hiemstra, Hilma J. van der Horst, Martine E.D. Chamuleau, A. Vera de Jonge, Margaretha G. M. Roemer, Tuna Mutis, Hendrik F. van Essen, Daniella R. A. I. Berry, Anne T. Gelderloos, Nathalie J. Hijmering, Sonja Zweegman, Daphne de Jong, Esther C.W. Breij
Publikováno v:
Blood Cancer Journal
Blood cancer journal, 11(2):38. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
van der Horst, H J, de Jonge, A V, Hiemstra, I H, Gelderloos, A T, Berry, D R A I, Hijmering, N J, van Essen, H F, de Jong, D, Chamuleau, M E D, Zweegman, S, Breij, E C W, Roemer, M G M & Mutis, T 2021, ' Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment ', Blood cancer journal, vol. 11, no. 2, 38 . https://doi.org/10.1038/s41408-021-00430-6
Blood cancer journal, 11(2):38. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
van der Horst, H J, de Jonge, A V, Hiemstra, I H, Gelderloos, A T, Berry, D R A I, Hijmering, N J, van Essen, H F, de Jong, D, Chamuleau, M E D, Zweegman, S, Breij, E C W, Roemer, M G M & Mutis, T 2021, ' Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment ', Blood cancer journal, vol. 11, no. 2, 38 . https://doi.org/10.1038/s41408-021-00430-6
Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f0a7136b198a975ec95c1bb3014164d
http://europepmc.org/articles/PMC7892878
http://europepmc.org/articles/PMC7892878
Autor:
Anne T. Gelderloos, Hilma J. van der Horst, Margaretha G. M. Roemer, Daphne de Jong, Ida H. Hiemstra, Nathalie J. Hijmering, Tuna Mutis, A. Vera de Jonge, Martine E.D. Chamuleau, Daniella R. A. I. Berry, Sonja Zweegman, Esther C.W. Breij
Publikováno v:
Van der Horst, H J, de Jonge, A V, Hiemstra, I H, Gelderloos, A T, Berry, D R, Hijmering, N J, de Jong, D, Chamuleau, M E D, Zweegman, S, Breij, E C W, Roemer, M G M & Mutis, T 2019, ' Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo, Irrespective of Prior Treatment with CD20 Monoclonal Antibodies ', Blood, vol. 134 . https://doi.org/10.1182/blood-2019-125765
Blood, 134. American Society of Hematology
Blood, 134. American Society of Hematology
DuoBody-CD3xCD20 (GEN3013) is a novel clinical-stage CD3 bispecific antibody (bsAb) targeting CD20-positive tumor cells. GEN3013 was previously shown to induce potent T cell-mediated cytotoxicity towards B cell Non-Hodgkin lymphoma (B-NHL) cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce8ea8693936bfc1c3467fb58ae0d8bb
https://research.vumc.nl/en/publications/e931762b-0464-4b7a-a847-952d9cf26c1b
https://research.vumc.nl/en/publications/e931762b-0464-4b7a-a847-952d9cf26c1b
Autor:
Laura Peferoen, Patrick M. Smit, Martine E.D. Chamuleau, Brigit A. de Jong, Mike P. Wattjes, Daphne de Jong, Daniella R. A. I. Berry, Zoé L.E. van Kempen
Publikováno v:
de Jong, BA, van Kempen, ZLE, Wattjes, MP, Smit, PM, Peferoen, LAN, Berry, D, Chamuleau, MED & de Jong, D 2018, ' Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod ', Neurology neuroimmunology & neuroinflammation, vol. 5, no. 5, e483 . https://doi.org/10.1212/NXI.0000000000000483
Neurology neuroimmunology & neuroinflammation, 5(5):e483. Lippincott Williams and Wilkins
Neurology® Neuroimmunology & Neuroinflammation
Neurology neuroimmunology & neuroinflammation, 5(5):e483. Lippincott Williams and Wilkins
Neurology® Neuroimmunology & Neuroinflammation
Fingolimod, an oral sphingosine 1-phosphate (S1P) receptor modulator, is an effective oral immune therapy for treatment of relapsing-remitting MS (RRMS).1 Development of solid malignancies was observed in large randomized phase-3 trials examining the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e61fe0315babc54ad19ca897d6f2f32
https://doi.org/10.1212/nxi.0000000000000483
https://doi.org/10.1212/nxi.0000000000000483